GlaxoSmithKline
Latest
WHO approves the world's first malaria vaccine
In a landmark announcement today, the World Health Organization has recommended the use of the first-ever malaria vaccine.
GSK to use 23andMe’s DNA library in drug development
DNA testing company 23andMe has partnered with pharmaceutical giant GlaxoSmithKline (GSK), in a bid to develop new drug treatments. 23andMe, which gives customers insight into their genetic makeup via postal saliva tests, has some five million customers -- a potential DNA database considerably larger than those generally available to the scientific community. "By working with GSK, we believe we will accelerate the development of breakthroughs," 23andMe CEO Anne Wojcicki wrote in a blog post.
GSK will use supercomputers to develop new drugs
Developing a new drug is a long, complicated and expensive process that takes years before you get to the human trial. There's a hope that computers will be able to simulate the majority of the process, greatly reducing the cost and time involved. That's why GlaxoSmithKline is throwing $43 million in the direction of Scottish AI company Exscientia, which promises to use deep learning to find new drugs.
Google teams up with GSK to develop 'bioelectronic medicines'
By forcing startups like Google X, Fiber and Nest to behave like companies and take financial accountability, Alphabet believes that its subsidiaries are more likely to invest in projects that will ultimately make it money. Being in the expensive healthcare business, Verily -- formerly Google Life Sciences -- often needs to speculate to accumulate, but for its latest venture, the company is dreaming big. It's teaming up with British pharmaceutical giant GlaxoSmithKline (GSK) to develop bioelectronic medicines that can "harness electrical signals in the body to treat chronic disease."
Apple entices its first big drug company to ResearchKit
Although Apple's ResearchKit is almost two years old, the platform has mainly been reserved for clinical studies hosted by universities and medical researchers. Hundreds of thousands of people are already contributing data for studies focusing on asthma, diabetes, breast cancer, autism, epilepsy and melanoma, but now drugmakers are getting in on the act. Almost a year after it said it was readying studies using Apple's health data-collecting tool, GlaxoSmithKline (GSK) has confirmed the launch of a new research app to help monitor patients with rheumatoid arthritis.
